Company: HSDTW
Filing Date: 2025-09-22
Form Type: S-3ASR
Source: 0001104659-25-091789
Chunk: 1

Company: Solana Co
Filing Date: 2025-09-22
Form: S-3ASR
Chunk 1
---
 this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒ If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| ​ | Large accelerated filer   ☐ | ​ | ​ | Accelerated filer   ☐         | ​ |
| ​ | Non-accelerated filer   ☒   | ​ | ​ | Smaller reporting company   ☒ | ​ |
| ​ | ​                           | ​ | ​ | Emerging growth company   ☐   | ​ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

TABLE OF CONTENTS

### PROSPECTUS

#### Helius Medical Technologies, Inc.

#### Common Stock

#### Preferred Stock

#### Debt Securities

#### Warrants

#### Units
**We may offer and sell the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the securities.

Each time we offer and sell securities, we will provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement, together with the documents we incorporate by reference, before you invest in any of our securities.

We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters